PROLOR Biotech to Present at Oppenheimer 23rd Annual Healthcare Conference

NES-ZIONA, Israel, Dec. 10, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT:PBTH) today announced that company management will give a corporate presentation at the Oppenheimer 23^rd Annual Healthcare Conference on December 12, 2012 at 9:25 am EST. The conference is being held December 12-13, 2012 at the Waldorf Astoria Hotel in New York City.

A live webcast of the company's presentation will be available at http://www.veracast.com/webcasts/opco/healthcare2012/14104417.cfm. An archived version of the webcast will be available for 90 days beginning about three hours after the live presentation.

For more information about the Oppenheimer 23^rd Annual Healthcare Conference, visit http://www.opco.com/Conferences/healthcare12/index.html.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit www.prolor-biotech.com.

SOURCE PROLOR Biotech, Inc.